Ipsen Relocates U.S. R&D To Cambridge, Mass., Biotech Hub
This article was originally published in The Pink Sheet Daily
The French pharma is the latest company to move its researchers closer to the center of vibrant academic and medical research in Cambridge, Mass.
You may also be interested in...
Bayer/Algeta’s Xofigo Brings New Mechanism To Prostate Cancer Field
FDA approved the first alpha particle-emitting radioactive therapeutic agent, Bayer/Algeta’s Xofigo (radium Ra 223 dichloride), for prostate cancer patients with symptomatic bone metastases, three months ahead of the expected PDUFA date.
Deals of the Week: Allergan/MAP, Actavis/Uteron, Baxter/Ipsen, and More
Allergan’s buyout of MAP Pharma is an unusual case of a deal centered on drug under the shadow of a “complete response” letter, but it’s not the only one. How does it compare to recent precedents.
Pfizer Revamps Neuroscience R&D – New Site, New Mandate, New Leadership
Pfizer has thoroughly revamped its approach to neuroscience R&D, emphasizing disease biology and neural circuitry, moving its research team from Groton, Conn. to Cambridge, Mass., and hiring an eminent neuroscientist to lead the group.